POST-TEST

Multiple Myeloma Update — Volume 1, Issue 1

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Because it is universally expressed on malignant plasma cells, which of the following antigens is an attractive target for CAR T-cell-directed therapy in MM?*
   a. BCMA
   b. CD19
   c. CD33

2. A study presented at the 2016 ASH Annual Meeting demonstrated that daratumumab ________ safely be administered via subcutaneous injection.*
   a. Could
   b. Could not

3. Which of the following proteasome inhibitors has demonstrated activity in myeloma affecting the central nervous system?*
   a. Bortezomib
   b. Ixazomib
   c. Carfilzomib
   d. Marizomib

4. Ibrutinib is FDA approved for the treatment of ________.
   a. Chronic graft-versus-host disease
   b. WM
   c. Both a and b
   d. Neither a nor b

5. Infusion-related reactions associated with the administration of daratumumab tend to persist over the course of the patient’s treatment.
   a. True
   b. False

6. Which of the following side effects is NOT associated with ixazomib therapy?
   a. Arthralgia
   b. Gastrointestinal toxicity
   c. Peripheral neuropathy
   d. All of the above

7. Sensitivity to venetoclax for MM has primarily been observed in patients with t(11;14) disease.*
   a. True
   b. False

8. The Phase III randomized ELOQUENT-2 study evaluating elotuzumab/lenalidomide/dexamethasone versus lenalidomide/dexamethasone ________ a significant improvement in progression-free survival with the addition of elotuzumab for patients with R/R MM.
   a. Demonstrated
   b. Did not demonstrate

9. Which of the following categories reflects the mechanism of action of isatuximab?*
   a. Anti-CD38 monoclonal antibody
   b. Anti-PD-1/PD-L1 antibody
   c. IMiD
   d. Proteasome inhibitor

10. Recent data presented from the Myeloma X and XI trials demonstrated that lenalidomide maintenance therapy improved outcomes for transplant-eligible patients with ________.
    a. High-risk MM
    b. Standard-risk MM
    c. Both a and b
    d. Neither a nor b

* The content of this question refers to drugs or the use of drugs that have not yet received FDA approval.